<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Comprehensive Cancer Collection &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/collections/diseasestate/comprehensive-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Dactinomycin tops methotrexate for gestational trophoblastic neoplasia</title>
		<link>http://www.thedoctorschannel.com/view/dactinomycin-tops-methotrexate-for-gestational-trophoblastic-neoplasia-2/</link>
		<pubDate>Fri, 28 Jan 2011 21:57:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Ob/Gyn]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Women’s Health]]></category>
		<category><![CDATA[choriocarcinoma]]></category>
		<category><![CDATA[dactinomycin]]></category>
		<category><![CDATA[Dr. Raymond J. Osborne]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>
		<category><![CDATA[low-risk gestational trophoblastic neoplasia]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/dactinomycin-tops-methotrexate-for-gestational-trophoblastic-neoplasia-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; For women with low-risk gestational trophoblastic neoplasia, dactinomycin given every 2 weeks had a higher complete response rate than weekly methotrexate in a multinational, phase III trial. Despite these findings, editorialist Dr. Carol Aghajanian believes that most physicians will continue to use methotrexate as first-line therapy because short- and long-term -]]></description>
		
			<media:content duration="1:59" medium="video">
		<media:title><![CDATA[Dactinomycin tops methotrexate for gestational trophoblastic neoplasia]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; For women with low-risk gestational trophoblastic neoplasia, dactinomycin given every 2 weeks had a higher complete response rate than weekly methotrexate in a multinational, phase III trial. Despite these findings, editorialist Dr. Carol Aghajanian believes that most physicians will continue to use methotrexate as first-line therapy because short- and long-term -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/dactinomycin-tops-methotrexate-for-gestational-trophoblastic-neoplasia-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4044.jpg"/>
	<media:keywords><![CDATA[choriocarcinoma,dactinomycin,Dr. Raymond J. Osborne,Journal of Clinical Oncology,low-risk gestational trophoblastic neoplasia]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Autofluorescence bronchoscopy advantageous in detection of lung cancer and precancer</title>
		<link>http://www.thedoctorschannel.com/view/autofluorescence-bronchoscopy-advantageous-in-detection-of-lung-cancer-and-precancer-2/</link>
		<pubDate>Fri, 28 Jan 2011 00:19:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pulmonary Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[AFB]]></category>
		<category><![CDATA[autofluorescence bronchoscopy]]></category>
		<category><![CDATA[Dr. Liangan Chen]]></category>
		<category><![CDATA[lung cancer]]></category>
		<category><![CDATA[preneoplastic lesions]]></category>
		<category><![CDATA[white light bronchoscopy]]></category>
		<category><![CDATA[WLB]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/autofluorescence-bronchoscopy-advantageous-in-detection-of-lung-cancer-and-precancer-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Compared to conventional white light bronchoscopy, autofluorescence bronchoscopy is more sensitive in detecting lung cancer and preneoplastic lesions, according to a meta-analysis conducted by investigators in China. Several studies have produced varying results for the diagnostic efficiency of autofluorescence bronchoscopy (AFB) compared with white light bronchoscopy (WLB), so Dr. Liangan -]]></description>
		
			<media:content duration="1:32" medium="video">
		<media:title><![CDATA[Autofluorescence bronchoscopy advantageous in detection of lung cancer and precancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Compared to conventional white light bronchoscopy, autofluorescence bronchoscopy is more sensitive in detecting lung cancer and preneoplastic lesions, according to a meta-analysis conducted by investigators in China. Several studies have produced varying results for the diagnostic efficiency of autofluorescence bronchoscopy (AFB) compared with white light bronchoscopy (WLB), so Dr. Liangan -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/autofluorescence-bronchoscopy-advantageous-in-detection-of-lung-cancer-and-precancer-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4042.jpg"/>
	<media:keywords><![CDATA[AFB,autofluorescence bronchoscopy,Dr. Liangan Chen,lung cancer,preneoplastic lesions,white light bronchoscopy,WLB]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Less invasive lung cancer staging strategy has multiple benefits: study</title>
		<link>http://www.thedoctorschannel.com/view/less-invasive-lung-cancer-staging-strategy-has-multiple-benefits-study-2/</link>
		<pubDate>Thu, 25 Nov 2010 00:49:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Critical Care]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Pulmonary Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[Dr. Jouke T. Annema]]></category>
		<category><![CDATA[endosonography]]></category>
		<category><![CDATA[Journal of the American Medical Association]]></category>
		<category><![CDATA[lung cancer]]></category>
		<category><![CDATA[mediastinal nodal staging]]></category>
		<category><![CDATA[mediastinoscopy]]></category>
		<category><![CDATA[metastases]]></category>
		<category><![CDATA[unnecessary thoracotomies]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/less-invasive-lung-cancer-staging-strategy-has-multiple-benefits-study-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Initiating mediastinal nodal staging of suspected lung cancer with endosonography, followed by surgical staging (mediastinoscopy) if needed, improves the detection of metastases and reduces the rate of unnecessary thoracotomies, compared with surgical staging alone. These are the findings of a large randomized controlled trial released online today in the Journal -]]></description>
		
			<media:content duration="1:50" medium="video">
		<media:title><![CDATA[Less invasive lung cancer staging strategy has multiple benefits: study]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Initiating mediastinal nodal staging of suspected lung cancer with endosonography, followed by surgical staging (mediastinoscopy) if needed, improves the detection of metastases and reduces the rate of unnecessary thoracotomies, compared with surgical staging alone. These are the findings of a large randomized controlled trial released online today in the Journal -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/less-invasive-lung-cancer-staging-strategy-has-multiple-benefits-study-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3885.jpg"/>
	<media:keywords><![CDATA[Dr. Jouke T. Annema,endosonography,Journal of the American Medical Association,lung cancer,mediastinal nodal staging,mediastinoscopy,metastases,unnecessary thoracotomies]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Percutaneous or surgical cryoablation equivalent for small renal masses</title>
		<link>http://www.thedoctorschannel.com/view/percutaneous-or-surgical-cryoablation-equivalent-for-small-renal-masses-2/</link>
		<pubDate>Mon, 22 Nov 2010 22:43:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[Urology]]></category>
		<category><![CDATA[BJU International]]></category>
		<category><![CDATA[cryoablation]]></category>
		<category><![CDATA[cryotherapy]]></category>
		<category><![CDATA[Dr. Robert Uzzo]]></category>
		<category><![CDATA[small renal masses]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/percutaneous-or-surgical-cryoablation-equivalent-for-small-renal-masses-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Outcomes of cryoablation of small renal masses are similar whether the procedure is performed surgically or percutaneously, according the results of a meta-analysis published in BJU International. “There are distinct theoretical advantages and disadvantages to each strategy,” write Dr. Robert Uzzo, with the Fox Chase Cancer Center in Philadelphia, Pennsylvania, -]]></description>
		
			<media:content duration="1:16" medium="video">
		<media:title><![CDATA[Percutaneous or surgical cryoablation equivalent for small renal masses]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Outcomes of cryoablation of small renal masses are similar whether the procedure is performed surgically or percutaneously, according the results of a meta-analysis published in BJU International. “There are distinct theoretical advantages and disadvantages to each strategy,” write Dr. Robert Uzzo, with the Fox Chase Cancer Center in Philadelphia, Pennsylvania, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/percutaneous-or-surgical-cryoablation-equivalent-for-small-renal-masses-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3870.jpg"/>
	<media:keywords><![CDATA[BJU International,cryoablation,cryotherapy,Dr. Robert Uzzo,small renal masses]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Oral fluoropyrimidine derivative with carboplatin an option for non-small-cell lung cancer</title>
		<link>http://www.thedoctorschannel.com/view/oral-fluoropyrimidine-derivative-with-carboplatin-an-option-for-non-small-cell-lung-cancer-2/</link>
		<pubDate>Fri, 19 Nov 2010 23:04:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[chemotherapy-naive]]></category>
		<category><![CDATA[Dr. Isamu Okamoto]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>
		<category><![CDATA[non-small-cell lung cancer]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[oral fluoropyrimidine derivative S-1]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/oral-fluoropyrimidine-derivative-with-carboplatin-an-option-for-non-small-cell-lung-cancer-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; In terms of overall survival, carboplatin plus the oral fluoropyrimidine derivative S-1 is as effective as carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC), according to the results of a phase III trial conducted in Japan. S-1 is “an oral fluoropyrimidine agent that consists of tegafur, -]]></description>
		
			<media:content duration="1:53" medium="video">
		<media:title><![CDATA[Oral fluoropyrimidine derivative with carboplatin an option for non-small-cell lung cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; In terms of overall survival, carboplatin plus the oral fluoropyrimidine derivative S-1 is as effective as carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC), according to the results of a phase III trial conducted in Japan. S-1 is “an oral fluoropyrimidine agent that consists of tegafur, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/oral-fluoropyrimidine-derivative-with-carboplatin-an-option-for-non-small-cell-lung-cancer-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3868.jpg"/>
	<media:keywords><![CDATA[carboplatin,chemotherapy-naive,Dr. Isamu Okamoto,Journal of Clinical Oncology,non-small-cell lung cancer,NSCLC,oral fluoropyrimidine derivative S-1,paclitaxel]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Denosumab effective for breast cancer-related bone metastases</title>
		<link>http://www.thedoctorschannel.com/view/denosumab-effective-for-breast-cancer-related-bone-metastases-2/</link>
		<pubDate>Fri, 12 Nov 2010 22:28:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Women’s Health]]></category>
		<category><![CDATA[Dr. Alison T. Stopeck]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>
		<category><![CDATA[monoclonal antibody denosumab]]></category>
		<category><![CDATA[zoledronic acid]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/denosumab-effective-for-breast-cancer-related-bone-metastases-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Compared with zoledronic acid, the monoclonal antibody denosumab is more effective in delaying skeletal-related events in women with breast cancer that has metastasized to bone, according to the results of a new study. The finding is reported in the November 8 online issue of the Journal of Clinical Oncology by -]]></description>
		
			<media:content duration="1:28" medium="video">
		<media:title><![CDATA[Denosumab effective for breast cancer-related bone metastases]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Compared with zoledronic acid, the monoclonal antibody denosumab is more effective in delaying skeletal-related events in women with breast cancer that has metastasized to bone, according to the results of a new study. The finding is reported in the November 8 online issue of the Journal of Clinical Oncology by -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/denosumab-effective-for-breast-cancer-related-bone-metastases-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3847.jpg"/>
	<media:keywords><![CDATA[Dr. Alison T. Stopeck,Journal of Clinical Oncology,monoclonal antibody denosumab,zoledronic acid]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Gefitinib, erlotinib may slow CNS metastases in advanced lung cancer</title>
		<link>http://www.thedoctorschannel.com/view/gefitinib-erlotinib-may-slow-cns-metastases-in-advanced-lung-cancer-2/</link>
		<pubDate>Tue, 09 Nov 2010 23:30:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Neurology & Neurosurgery]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[advanced non-small cell lung cancer]]></category>
		<category><![CDATA[central nervous system metastases]]></category>
		<category><![CDATA[Clinical Cancer Research]]></category>
		<category><![CDATA[Dr. Bruce E. Johnson]]></category>
		<category><![CDATA[EGFR mutations]]></category>
		<category><![CDATA[erlotinib]]></category>
		<category><![CDATA[gefitinib]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[tyrosine kinase inhibitors]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/gefitinib-erlotinib-may-slow-cns-metastases-in-advanced-lung-cancer-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; The tyrosine kinase inhibitors gefitinib or erlotinib may slow the development of central nervous system metastases in patients with advanced non-small cell lung cancer (NSCLC), if they carry sensitizing EGFR mutations. Those findings come from a Boston-based team, reporting in the October 28 online issue of Clinical Cancer Research. Dr. -]]></description>
		
			<media:content duration="1:28" medium="video">
		<media:title><![CDATA[Gefitinib, erlotinib may slow CNS metastases in advanced lung cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; The tyrosine kinase inhibitors gefitinib or erlotinib may slow the development of central nervous system metastases in patients with advanced non-small cell lung cancer (NSCLC), if they carry sensitizing EGFR mutations. Those findings come from a Boston-based team, reporting in the October 28 online issue of Clinical Cancer Research. Dr. -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/gefitinib-erlotinib-may-slow-cns-metastases-in-advanced-lung-cancer-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3837.jpg"/>
	<media:keywords><![CDATA[advanced non-small cell lung cancer,central nervous system metastases,Clinical Cancer Research,Dr. Bruce E. Johnson,EGFR mutations,erlotinib,gefitinib,NSCLC,tyrosine kinase inhibitors]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Taxane-based breast cancer treatments linked to amenorrhea risk</title>
		<link>http://www.thedoctorschannel.com/view/taxane-based-breast-cancer-treatments-linked-to-amenorrhea-risk-2/</link>
		<pubDate>Fri, 05 Nov 2010 21:58:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Women’s Health]]></category>
		<category><![CDATA[amenorrheic]]></category>
		<category><![CDATA[anthracycline-taxane based regimens]]></category>
		<category><![CDATA[anthracyclines]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[conventional chemotherapy]]></category>
		<category><![CDATA[Dr. Safa Najafi]]></category>
		<category><![CDATA[menopause]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/taxane-based-breast-cancer-treatments-linked-to-amenorrhea-risk-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Women with breast cancer treated with anthracycline-taxane based regimens are more likely to become amenorrheic than women treated with just anthracyclines or conventional chemotherapy, an Iranian study indicates. Dr. Safa Najafi with the Iranian Center for Breast Cancer in Tehran, and colleagues point out in their report in the October -]]></description>
		
			<media:content duration="1:22" medium="video">
		<media:title><![CDATA[Taxane-based breast cancer treatments linked to amenorrhea risk]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Women with breast cancer treated with anthracycline-taxane based regimens are more likely to become amenorrheic than women treated with just anthracyclines or conventional chemotherapy, an Iranian study indicates. Dr. Safa Najafi with the Iranian Center for Breast Cancer in Tehran, and colleagues point out in their report in the October -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/taxane-based-breast-cancer-treatments-linked-to-amenorrhea-risk-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3825.jpg"/>
	<media:keywords><![CDATA[amenorrheic,anthracycline-taxane based regimens,anthracyclines,breast cancer,conventional chemotherapy,Dr. Safa Najafi,menopause]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Guideline on epoetin/darbepoetin use in cancer patients stresses lowest dose to avoid transfusions</title>
		<link>http://www.thedoctorschannel.com/view/guideline-on-epoetindarbepoetin-use-in-cancer-patients-stresses-lowest-dose-to-avoid-transfusions-2/</link>
		<pubDate>Thu, 28 Oct 2010 19:57:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pathology & Lab Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Dr. J. Douglas Rizzo]]></category>
		<category><![CDATA[Dr. Melissa Brouwers]]></category>
		<category><![CDATA[Erythropoiesis-Stimulating Agents]]></category>
		<category><![CDATA[ESAs]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>
		<category><![CDATA[myelosuppressive chemotherapy]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/guideline-on-epoetindarbepoetin-use-in-cancer-patients-stresses-lowest-dose-to-avoid-transfusions-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; In order to minimize the risk of potential harms, erythropoiesis-stimulating agents (ESAs) in patients undergoing myelosuppressive chemotherapy should be administered at the lowest dose needed to raise hemoglobin to the minimum necessary level to avoid transfusions, according to updated recommendations from the American Society of Clinical Oncology and American Society -]]></description>
		
			<media:content duration="1:22" medium="video">
		<media:title><![CDATA[Guideline on epoetin/darbepoetin use in cancer patients stresses lowest dose to avoid transfusions]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; In order to minimize the risk of potential harms, erythropoiesis-stimulating agents (ESAs) in patients undergoing myelosuppressive chemotherapy should be administered at the lowest dose needed to raise hemoglobin to the minimum necessary level to avoid transfusions, according to updated recommendations from the American Society of Clinical Oncology and American Society -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/guideline-on-epoetindarbepoetin-use-in-cancer-patients-stresses-lowest-dose-to-avoid-transfusions-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3790.jpg"/>
	<media:keywords><![CDATA[Dr. J. Douglas Rizzo,Dr. Melissa Brouwers,Erythropoiesis-Stimulating Agents,ESAs,Journal of Clinical Oncology,myelosuppressive chemotherapy]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Fertility Preservation for Women &#8211; Part 2</title>
		<link>http://www.thedoctorschannel.com/view/fertility-preservation-for-women-part-2-2/</link>
		<pubDate>Thu, 28 Oct 2010 00:59:00 +0000</pubDate> 
				<category><![CDATA[Comprehensive Cancer Collection]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Ob/Gyn]]></category>
		<category><![CDATA[Public Health & Prevention]]></category>
		<category><![CDATA[Sexual Medicine]]></category>
		<category><![CDATA[Women’s Health]]></category>
		<category><![CDATA[Emre U Seli]]></category>
		<category><![CDATA[Fertility preservation]]></category>
		<category><![CDATA[infertility]]></category>
		<category><![CDATA[Third Party Reproduction Program Yale University]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/fertility-preservation-for-women-part-2-2/</guid>
		<description><![CDATA[Emru U. Seli, MD, Assistant Professor and Director of the Third Party Reproductive Program at Yale University, discusses fertility preservation for women who are about to undergo treatment that may compromise her fertility, such as chemotherapy or removal of ovaries. Related ReadingFertility preservation in young women with epithelial ovarian cancer.Wright JD, Shah M, Mathew L, -]]></description>
		
			<media:content duration="1:09" medium="video">
		<media:title><![CDATA[Fertility Preservation for Women &#8211; Part 2]]></media:title>
	<media:description><![CDATA[Emru U. Seli, MD, Assistant Professor and Director of the Third Party Reproductive Program at Yale University, discusses fertility preservation for women who are about to undergo treatment that may compromise her fertility, such as chemotherapy or removal of ovaries. Related ReadingFertility preservation in young women with epithelial ovarian cancer.Wright JD, Shah M, Mathew L, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/fertility-preservation-for-women-part-2-2/collection/collection-comprehensive-cancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3781.jpg"/>
	<media:keywords><![CDATA[Emre U Seli,Fertility preservation,infertility,Third Party Reproduction Program Yale University]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
